Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae | Zendy

David M. Livermore | Zendy; Shazad Mushtaq | Zendy; Michel Doumith | Zendy; Dorota Jamrozy | Zendy; Wright W. Nichols | Zendy; Neil Woodford | Zendy

Open Access

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae

Author(s) -

David M. Livermore,

Shazad Mushtaq,

Michel Doumith,

Dorota Jamrozy,

Wright W. Nichols,

Neil Woodford

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky363

Subject(s) - ceftazidime , avibactam , ceftazidime/avibactam , microbiology and biotechnology , enterobacteriaceae , biology , enterobacter cloacae , cephalosporin , mutant , antibiotics , escherichia coli , bacteria , gene , genetics , pseudomonas aeruginosa

Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam. Disturbingly, mutations in KPC carbapenemases can confer ceftazidime/avibactam resistance, which is sometimes selected during therapy. We explored whether this risk extended to AmpC and ESBL enzymes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research